SCHEMBL23043859

SCHEMBL23043859

Cc1cc(NC(=O)Cc2cccc(Cl)c2)ccc1-c1cn(C)c2ncnc(N)c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EIF2AK3 Q9NZJ5 7/20 0.54
▸ EIF2AK2 P19525 1/20 0.54
▸ EIF2AK1 Q9BQI3 1/20 0.54
▸ KDR P35968 3/20 0.51
▸ PLK4 O00444 1/20 0.51
▸ AURKA O14965 1/20 0.51
▸ DYRK3 O43781 1/20 0.51
▸ PRKD3 O94806 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51
▸ LCK P06239 1/20 0.51
▸ FYN P06241 1/20 0.51
▸ FES P07332 1/20 0.51
▸ CSF1R P07333 1/20 0.51
▸ LYN P07948 1/20 0.51
▸ FGFR1 P11362 1/20 0.51
▸ SRC P12931 1/20 0.51
▸ FLT1 P17948 1/20 0.51
▸ AXL P30530 1/20 0.51
▸ FLT4 P35916 1/20 0.51
▸ FLT3 P36888 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29746859 1.00 EIF2AK3 (0.54) EIF2AK3EIF2AK2EIF2AK1KDRPLK4
SCHEMBL29746861 0.91 EIF2AK3 (0.54) EIF2AK3EIF2AK2EIF2AK1KDRAURKA
SCHEMBL29746729 0.91 RIPK1 (0.53) EIF2AK3EIF2AK2EIF2AK1KDRAURKA
SCHEMBL23044652 0.91 EIF2AK3 (0.54) EIF2AK3EIF2AK2EIF2AK1KDRAURKA
SCHEMBL23043888 0.91 RIPK1 (0.53) EIF2AK3EIF2AK2EIF2AK1KDRAURKA
SCHEMBL23043902 0.90 NTRK1 (0.51) EIF2AK3EIF2AK2EIF2AK1AXLFLT3
SCHEMBL29746677 0.90 NTRK1 (0.51) EIF2AK3EIF2AK2EIF2AK1AXLFLT3
SCHEMBL23044049 0.90 EIF2AK3 (0.51) EIF2AK3KDRCSF1RSRCAXL
SCHEMBL29746539 0.90 EIF2AK3 (0.51) EIF2AK3KDRCSF1RSRCAXL
SCHEMBL23044093 0.90 EIF2AK3 (0.54) EIF2AK3EIF2AK2EIF2AK1KDRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. 2022-11-10 — — US claimed
EP-4021908-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS Hibercell, Inc. (US) 2022-07-06 — — EP claimed
CN-114710956-A PERK-INHIBITING PYRROLOPYRIMIDINE COMPOUNDS 希伯塞尔股份有限公司 2022-07-05 — — CN claimed
WO-2021231788-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS HIBERCELL, INC. (US) 2021-11-18 — — WO claimed
WO-2021041975-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 — — WO claimed
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. 2022-11-10 — — US disclosed
EP-4021908-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS Hibercell, Inc. (US) 2022-07-06 — — EP disclosed
CN-114710956-A PERK-INHIBITING PYRROLOPYRIMIDINE COMPOUNDS 希伯塞尔股份有限公司 2022-07-05 — — CN disclosed
WO-2021231788-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS TO TREAT VIRAL INFECTIONS HIBERCELL, INC. (US) 2021-11-18 — — WO disclosed
WO-2021041975-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 — — WO disclosed
WO-2021041975-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS EEF2K, ATF4, MAPKAPK2 EIF2AK3 96/4885EIF2AK2 37/4885EIF2AK1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback